Kairos Pharma, LTD. cotiza a 0.83 USD y tiene una capitalización bursátil de $3M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, …
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.42 | $-0.56 | $-0.49 | $-0.49 |
| Estimado | $-0.63 | $-0.49 | $0.21 | $-0.53 |
| Sorpresa | +33.3% | -14.3% | -333.3% | +7.5% |
| Métrica | KAPA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -85.9% | -40.4% | -45.5% |
| ROA | -83.3% | -32.0% | -51.3% |
| Current Ratio | 27.07 | 2.84 | +24.23 |
| Debt / Equity | — | 0.28 | — |